Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398104 | 0.83 | AR (0.46) | RAB9AMEN1KMT2ANPC1CYP3A4 | |
| SCHEMBL29746219 | 0.83 | AR (0.46) | RAB9AMEN1KMT2ANPC1CYP3A4 | |
| SCHEMBL27912984 | 0.81 | NPC1 (0.66) | TAAR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL4069431 | 0.80 | AR (0.44) | RAB9AMEN1KMT2ANPC1CYP3A4 | |
| SCHEMBL4070650 | 0.80 | RAB9A (0.41) | RAB9AMEN1KMT2ANPC1CYP3A4 | |
| SCHEMBL20809321 | 0.79 | DHODH (0.51) | RAB9AMEN1KMT2ANPC1CYP3A4 | |
| SCHEMBL20809062 | 0.79 | RAB9A (0.42) | RAB9AMEN1KMT2ANPC1CYP3A4 | |
| SCHEMBL10039876 | 0.77 | RAB9A (0.55) | RAB9AMEN1KMT2ANPC1CYP3A4 | |
| SCHEMBL20809323 | 0.76 | RAB9A (0.38) | RAB9AMEN1KMT2ANPC1CYP3A4 | |
| SCHEMBL23705909 | 0.76 | NPC1 (0.44) | RAB9AMEN1KMT2ANPC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261306-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261306-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261306-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-8513415-B2 | Preparation of C-pyrazine-methylamines | OSI Pharmaceuticals, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513415-B2 | Preparation of C-pyrazine-methylamines | OSI Pharmaceuticals, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513415-B2 | Preparation of C-pyrazine-methylamines | OSI Pharmaceuticals, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| CN-102405214-A | Preparation of c-pyrazine-methylamines | OSI PHARM INC | 2012-04-04 | — | — | CN | disclosed |
| EP-2421837-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI Pharmaceuticals, LLC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120041202-A1 | Preparation of C-Pyrazine-Methylamines | OSI Pharmaceuticals, LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120041202-A1 | Preparation of C-Pyrazine-Methylamines | OSI Pharmaceuticals, LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120041202-A1 | Preparation of C-Pyrazine-Methylamines | OSI Pharmaceuticals, LLC | 2012-02-16 | — | — | US | disclosed |
| WO-2010123792-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123792-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261306-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | DOT1L, INMT, H1-5 | TAAR1 107/4885RAB9A 1394/4885MEN1 208/4885 |
| US-20120041202-A1 | Preparation of C-Pyrazine-Methylamines | DOT1L, INMT, H1-5 | TAAR1 107/4885RAB9A 1394/4885MEN1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.